Crinetics Pharmaceuticals’ Post

View organization page for Crinetics Pharmaceuticals, graphic

18,876 followers

Congenital adrenal hyperplasia (CAH) is a rare endocrine disorder with significant unmet needs, impacting approximately 1 in 10,000 to 15,000 live births in the U.S. and Europe. Our Co-founder and Chief Scientific Officer, Stephen Betz, reflects on Crinetics' commitment to addressing the urgent needs of the CAH community. #CAHAwarenessMonth

Carol Tuggey

Immediate Past Chairperson of the Board of Directors at The Doris A. Howell Foundation for Women's Health Research

3mo

Great to see Steve talk about the research!!!

Like
Reply

To view or add a comment, sign in

Explore topics